On January15, 2019, Chris Stevens, M.D., the Chief Medical Officer of Arsanis, Inc. (the Company), stepped down from the Company, effective immediately.
On January11, 2019, the Compensation Committee of the Companys Board of Directors resolved that, effective upon the termination of Dr.Stevens employment with the Company, the vesting schedule of any outstanding stock options and other equity awards previously granted to Dr.Stevens would be accelerated in full.
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: January16, 2019
/s/ Michael P. Gray
Michael P. Gray
President and Chief Executive Officer
makes a similar move, sign up!
Other recent filings from the company include the following:
Departure of Directors or Certain - March 20, 2020
Entry into a Material Definitive - March 17, 2020
Securities to be offered to employees in employee benefit plans - March 13, 2020
Arsanis, Inc. Just Filed Its Annual Report: Net Loss per Share— ... - March 12, 2020
Arsanis: X4 Pharmaceuticals Provides Corporate Update And Reports Fourth Quarter And Full Year 2019 Financial Results - March 12, 2020